Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (111-120 of 193) with videos related to

Pageof 20
Sort By:
Leukemia Research|February 19, 2013
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemiaDaniela Cilloni, Sonia Carturan, Enrico Bracco, et al.
Haematologica|June 11, 2010
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavengingEmanuela Messa, Sonia Carturan, Chiara Maffè, et al.
Biomarker Research|July 7, 2015
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISHValentina Rosso, Enrico Bracco, Roberto Pedrola, et al.
British Journal of Haematology|November 9, 2018
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)Emiliano Fabiani, Chiara Calabrese, Pasquale Niscola, et al.
Oncotarget|January 14, 2016
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantationLuciana De Luca, Stefania Trino, Ilaria Laurenzana, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Oncotarget|April 19, 2017
Epha3 acts as proangiogenic factor in multiple myelomaAntonella Caivano, Francesco La Rocca, Ilaria Laurenzana, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemiaSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Pageof 20

Showing results (111-120 of 193) with videos related to

Sort By:
Pageof 20
Leukemia Research|February 19, 2013
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemiaDaniela Cilloni, Sonia Carturan, Enrico Bracco, et al.
Haematologica|June 11, 2010
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavengingEmanuela Messa, Sonia Carturan, Chiara Maffè, et al.
Biomarker Research|July 7, 2015
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISHValentina Rosso, Enrico Bracco, Roberto Pedrola, et al.
British Journal of Haematology|November 9, 2018
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS)Emiliano Fabiani, Chiara Calabrese, Pasquale Niscola, et al.
Oncotarget|January 14, 2016
MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantationLuciana De Luca, Stefania Trino, Ilaria Laurenzana, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Oncotarget|April 19, 2017
Epha3 acts as proangiogenic factor in multiple myelomaAntonella Caivano, Francesco La Rocca, Ilaria Laurenzana, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemiaSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Pageof 20